SCHEMBL29357445

SCHEMBL29357445

CC(C)(C)OC(=O)N1CCc2[nH]c3cc(F)ccc3c2C1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ BAZ2B Q9UIF8 7/20 0.58
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ PABPC1 P11940 1/20 0.50
▸ ATM Q13315 1/20 0.50
▸ MAPT P10636 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ CTSK P43235 2/20 0.48
▸ CFTR P13569 2/20 0.48
▸ CTSB P07858 1/20 0.47
▸ GAA P10253 1/20 0.46
▸ ESR2 Q92731 1/20 0.45
▸ BRD3 Q15059 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21114805 1.00 BAZ2B (0.58) BAZ2BSMN1; SMN2LMNAPABPC1ATM
SCHEMBL21588267 0.91 TRPV1 (0.51) BAZ2BESR2BRD3
SCHEMBL5104575 0.91 BAZ2B (0.71) BAZ2BSMN1; SMN2LMNAPABPC1ATM
SCHEMBL21153987 0.90 BAZ2B (0.47) BAZ2BSMN1; SMN2MAPTALDH1A1KDM4E
SCHEMBL16441048 0.88 LMNA (0.62) BAZ2BSMN1; SMN2LMNAPABPC1ATM
SCHEMBL29983936 0.87 BAZ2B (0.58) BAZ2BSMN1; SMN2LMNAPABPC1ATM
SCHEMBL3475272 0.87 BAZ2B (0.58) BAZ2BSMN1; SMN2LMNAPABPC1ATM
SCHEMBL21114768 0.86 BAZ2B (0.61) BAZ2BSMN1; SMN2LMNAPABPC1ATM
SCHEMBL30506408 0.86 BAZ2B (0.61) BAZ2BSMN1; SMN2LMNAPABPC1ATM
SCHEMBL31117582 0.85 BAZ2B (0.60) BAZ2BSMN1; SMN2LMNAPABPC1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3941477-A1 NOVEL COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES AC Immune SA (CH) 2022-01-26 — — EP disclosed
Send feedback